Women with epithelial ovarian cancer need a reliable test to determine if they are eligible for PARP inhibitor treatment. It may also be helpful to know if they are at risk for other cancers. TumorNext-HRD looks at both tumor and germline so that you can get the complete picture and provide timely targeted treatment to patients at a time when they need it most.
Quick Reference
Test Code: 9810 Test Name: TumorNext- BRCA TAT 3-4 weeks Genes: 2
Test Code: 9811 Test Name: TumorNext- HRD TAT 3-4 weeks Genes: 11

Ordering Options

We now offer single site analysis (SSA) at no additional cost to family members

following single gene or panel testing* of the first family member (proband) within 90 days of the original Ambry report date.

Order Now

*excludes Exome and SNP Array tests

Why Is This Important?

Tests that look at only tumor tissue do not allow you to identify patients with hereditary cancer and those that look at only germline will miss patients who may benefit from PARP inhibitors. TumorNext-HRD does both by detecting and differentiating between germline and somatic mutations in homologous recombination repair genes including BRCA1 and BRCA2 in one simple test so that you can:

  1. Identify ovarian cancer patients who are at an increased risk for other cancers
  2. Identify patients who have family members that may be at a significantly increased risk for cancer and clarify management recommendations
  3. Determine which patients may benefit from targeted treatment with PARP inhibitors
  4. Increase diagnostic yield by including methylation status and additional HRD genes


When To Consider Testing

Use TumorNext-HRD for your ovarian cancer patients to determine who may be eligible for PARP inhibitor treatment or future eligibility. 

  • NCCN® recommends BRCA1/2 germline testing for all patients with epithelial ovarian cancer.
  • SGO recommends that all women diagnosed with epithelial ovarian, fallopian tube, and peritoneal cancers should consider genetic testing, even in the absence of a family history of cancer.

Test Description

Paired tumor/germline analysis of BRCA1/BRCA2 plus 9 additional genes* in the homologous recombination repair pathway that are also known to be associated with hereditary cancer, and also includes BRCA1 and RAD51C methylation analysis.

Additional genes on TumorNext-HRD: ATM, BARD1, BRIP1, CHEK2, MRE11A, NBN, PALB2, RAD51C, RAD51D

View Full Menu

Search Results

Start your search...